ArticleJournal of cardiovascular pharmacology2018
Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.
Article in Journal of cardiovascular pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- The horse cardiac transcriptome: Moving towards a molecular understanding of atrial fibrillation.Equine veterinary journal · 2026Article
- Unraveling the pharmacological and therapeutic potential of Ranolazine beyond antianginal drug use: a new insight.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- "Pharmacological" analysis of atrial fibrillation maintenance mechanism: reentry, wavelets, or focal?Frontiers in cardiovascular medicine · 2025Review
- Therapeutic advances in atrial fibrillation based on animal models.Journal of Zhejiang University. Science. B · 2024Review
- Long-Term Training Increases Atrial Fibrillation Sustainability in Standardbred Racehorses.Journal of cardiovascular translational research · 2023Article
- Emerging Antiarrhythmic Drugs for Atrial Fibrillation.International journal of molecular sciences · 2022Review
- Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.Pharmaceuticals (Basel, Switzerland) · 2021Review
- "Ranolaziodarone"-A Synergism You Should Not Miss.The Journal of innovations in cardiac rhythm management · 2021Article
- Inhibition of Small-Conductance Calcium-Activated Potassium Current (Frontiers in physiology · 2021Article
- First catheter-based high-density endocardial 3D electroanatomical mapping of the right atrium in standing horses.Equine veterinary journal · 2021Article
- Antiarrhythmic Effect of Ranolazine in Combination with Selective NCX-Inhibition in an Experimental Model of Atrial Fibrillation.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Effect of selective IBritish journal of pharmacology · 2020Article
- Longitudinal study of electrical, functional and structural remodelling in an equine model of atrial fibrillation.BMC cardiovascular disorders · 2019Article
- Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation.Journal of cardiovascular electrophysiology · 2019Article
- Time-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses.Journal of veterinary internal medicine · 2018Article
- Multiple Catheter Recording in Horses to Investigate Atrial Depolarization Pattern During Sinus Rhythm and Induced Premature Atrial Complexes.Journal of veterinary internal medicineArticle
- Ranolazine: Multifaceted Role beyond Coronary Artery Disease, a Recent Perspective.Heart views : the official journal of the Gulf Heart AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiarrhythmic compounds against atrial fibrillation (AF) often have reduced efficacy and may display cardiac and/or noncardiac toxicity. Efficacy can be improved by combining 2 compounds with distinct mechanisms, and it may be possible to use lower doses of each compound, thereby reducing the likelihood of adverse side effects. The purpose of this study was to investigate whether the effective doses of dofetilide and ranolazine can be reduced if the drugs are combined.
methodsDofetilide, ranolazine, and a combination of these were administered in 4 incremental dosing regimens to horses with acutely pacing-induced AF. Time to cardioversion, atrial effective refractory period, and AF vulnerability and duration were assessed.
resultsOf 8 horses, 6 cardioverted to sinus rhythm after infusion with a combination of 0.889 μg/kg dofetilide and 0.104 mg/kg ranolazine. Two horses cardioverted with 0.104 mg/kg ranolazine alone, and 3 cardioverted with 0.889 μg/kg dofetilide alone. The combination therapy decreased AF vulnerability (P < 0.05) and AF duration (P < 0.05). No change in atrial effective refractory period was detected with any of the drugs.
conclusionsThe combination of dofetilide and ranolazine showed increased antiarrhythmic effects on acutely induced AF in horses, affecting time to cardioversion, AF vulnerability, and AF duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.